Previous 10 | Next 10 |
( Pexels ) Of all the investable sectors and industries, one of the top-performing over the past few months is biotechnology. Since its March low (18 th ), the SPDR Biotech ETF ( XBI ) has risen about 75% as investors speculate on virus treatment and vaccine rumors. Understandably, many in...
I think the biggest innovations of the 21st century will be the intersection of biology and technology. A new era is beginning. Steve Jobs Invitae ( NVTA ) is a market leader in genetic testing, the company is growing at full speed and it has enormous room for further growth in the years...
Genetic testing is a way to identify how chromosomes, genes and proteins change, according to the US National Library of Medicine . So what are the top genetic testing stocks? There are currently thousands of genetic tests, with more being developed. As noted by the US National Library of...
In the past three months alone, shares of genetic testing company Invitae (NYSE: NVTA) have soared by 90%. In fact, the company's shares outperformed the S&P 500's return of 25% by nearly five times during the same period. At this rate, investors may be wondering: Could Invitae be a mill...
NEW YORK , June 26, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Invitae Corporation (NYSE: NVTA) and ArcherDX is fair to Invitae shareholders. On behalf of Invitae shareholders, Halper Sadeh LLP may seek increased c...
Illumina (NASDAQ: ILMN) and Invitae (NYSE: NVTA) are two exciting genetic testing companies at dramatically different phases of the corporate lifecycle. For investors seeking a balanced biotech portfolio , there's a lot to appreciate about each of these companies, both of which look to ...
June 23, 2020 Palm Beach, FL –June 23, 2020 – Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT hopeless. Many people continue to li...
Invitae (NYSE: NVTA) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around $1.4 billion. Under the terms of the deal, Invitae will provide $325 million in cash and 30 million shares of Invitae common stock upfront. In addition, anoth...
Shares of Invitae (NYSE: NVTA) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. At a total transaction cost of $1.4 billion, it's easily the largest acquisition in the company's history. The combination will immediately boost Invitae's product offer...
Gainers: Sintx Technologies (NASDAQ: SINT ) +169% . More news on: Sintx Technologies, Inc., Evoke Pharma, Inc., Ideanomics, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...